ATE298569T1 - Virus behandlung - Google Patents

Virus behandlung

Info

Publication number
ATE298569T1
ATE298569T1 AT00919868T AT00919868T ATE298569T1 AT E298569 T1 ATE298569 T1 AT E298569T1 AT 00919868 T AT00919868 T AT 00919868T AT 00919868 T AT00919868 T AT 00919868T AT E298569 T1 ATE298569 T1 AT E298569T1
Authority
AT
Austria
Prior art keywords
virus treatment
virus
treatment
Prior art date
Application number
AT00919868T
Other languages
English (en)
Inventor
James Berger Camden
Joseph Herman Gardner
David Thomas Stanton
Original Assignee
Uaf Technologies And Res Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uaf Technologies And Res Llc filed Critical Uaf Technologies And Res Llc
Application granted granted Critical
Publication of ATE298569T1 publication Critical patent/ATE298569T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
AT00919868T 1999-03-31 2000-03-29 Virus behandlung ATE298569T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28189299A 1999-03-31 1999-03-31
PCT/US2000/008419 WO2000057870A2 (en) 1999-03-31 2000-03-29 Viral treatment

Publications (1)

Publication Number Publication Date
ATE298569T1 true ATE298569T1 (de) 2005-07-15

Family

ID=23079205

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00919868T ATE298569T1 (de) 1999-03-31 2000-03-29 Virus behandlung

Country Status (11)

Country Link
US (2) US6194430B1 (de)
EP (1) EP1165077B1 (de)
JP (1) JP2002540151A (de)
AR (1) AR018706A1 (de)
AT (1) ATE298569T1 (de)
AU (1) AU763431B2 (de)
CA (1) CA2365495C (de)
CO (1) CO5160292A1 (de)
DE (1) DE60021065T2 (de)
NZ (1) NZ514558A (de)
WO (1) WO2000057870A2 (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6969367B2 (en) * 2000-02-02 2005-11-29 Xepmed, Inc. Extracorporeal pathogen reduction system
US6613507B1 (en) 2000-03-21 2003-09-02 Yu-an Chang Boraadamantane compounds for the treatment of pathogenic viruses and other medical applications
GEP20043285B (en) 2000-03-30 2004-07-26 Bristol Myers Squibb Co Sustained Release Beadlets Containing Stavudine, Method for Their Production, Pharmaceutical Composition Containing the Same and Use Thereof for Treatment Retroviral Infections
WO2001097749A2 (en) * 2000-06-23 2001-12-27 Kotze, Gavin, Salomon The use of synthetic, non-hormonal 21-aminosteroids and thereof
AU2002239395A1 (en) * 2000-11-01 2002-06-03 The Procter And Gamble Company Hiv treatment with benzimidazoles
AU2003220585A1 (en) * 2002-03-26 2003-10-13 Arizona Board of Regents on behalf of the University of Arizone Solubilization of weak bases
US7615223B2 (en) * 2002-07-15 2009-11-10 Board Of Regents, The University Of Texas System Selected immunoconjugates for binding to aminophospholipids
EP2283868B1 (de) * 2002-07-15 2016-03-30 Board of Regents, The University of Texas System Peptide mit Bindung an Phosphatidylethanolamine und ihre Verwendung bei der Behandlung von Virusinfektionen und Krebs
US7622118B2 (en) * 2002-07-15 2009-11-24 Board Of Regents, The University Of Texas System Cancer treatment methods using selected antibodies to aminophospholipids
US7625563B2 (en) * 2002-07-15 2009-12-01 Board Of Regents, The University Of Texas System Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids
US7572448B2 (en) * 2002-07-15 2009-08-11 Board Of Regents, The University Of Texas System Combined cancer treatment methods using selected antibodies to aminophospholipids
US7678386B2 (en) 2002-07-15 2010-03-16 Board Of Regents The University Of Texas Liposomes coated with selected antibodies that bind to aminophospholipids
US7714109B2 (en) * 2002-07-15 2010-05-11 Board Of Regents, The University Of Texas System Combinations and kits for cancer treatment using selected antibodies to aminophospholipids
US20070053883A1 (en) * 2003-03-25 2007-03-08 The Johns Hopkins University Neuronal cell lineages and methods of production thereof
US20080027575A1 (en) * 2006-04-21 2008-01-31 Jones Stevan D Modeling systems for health and beauty consumer goods
CN110294751B (zh) * 2018-03-21 2020-11-20 湖南化工研究院有限公司 具生物活性的咪唑[4,5-b]并吡啶类化合物及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3590045A (en) 1969-09-25 1971-06-29 Smith Kline French Lab Certain substituted imidazo (4,5-b)pyridines
IL37752A (en) 1970-09-21 1974-10-22 Rhone Poulenc Sa Imidazo(4,5-b)pyridine-2-carbamic acid derivatives,processes for their preparation and pharmaceutical and veterinary compositions containing the same
AT379395B (de) * 1983-11-14 1985-12-27 Laevosan Gmbh & Co Kg Verfahren zur herstellung von neuen 2(2-thienyl)-imidazo (4,5-b) pyridin-derivaten und deren pharmazeutisch vertraeglichen saeureadditionssalzen
DE3722992A1 (de) * 1987-07-11 1989-01-19 Thomae Gmbh Dr K Neue imidazo-pyridine und purine, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
DE60021065D1 (de) 2005-08-04
WO2000057870A3 (en) 2001-03-08
CO5160292A1 (es) 2002-05-30
WO2000057870A2 (en) 2000-10-05
US6194430B1 (en) 2001-02-27
AU4048900A (en) 2000-10-16
NZ514558A (en) 2004-02-27
DE60021065T2 (de) 2006-06-01
AR018706A1 (es) 2001-11-28
CA2365495C (en) 2007-01-02
US20030232851A1 (en) 2003-12-18
JP2002540151A (ja) 2002-11-26
EP1165077A2 (de) 2002-01-02
AU763431B2 (en) 2003-07-24
CA2365495A1 (en) 2000-10-05
EP1165077B1 (de) 2005-06-29

Similar Documents

Publication Publication Date Title
DE60001421D1 (de) Behandlung von abgas
FI20000863A0 (fi) Uusi hoitomenetelmä
DE60019556D1 (de) 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit
DE60019555D1 (de) 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit
DE69925306D1 (de) Behandlung von kohlenwasserstoffgas
ID29550A (id) Quinolinakarboksamida sebagai agen-agen antivirus
DE69915087D1 (de) Behandlung von textilien
DE60012138D1 (de) Gerät zur behandlung von fibrillation
DE60136477D1 (de) Retinoide zur behandlung von emphysem
NO20005179D0 (no) Medikament behandling
NO20032122L (no) Forbedret behandling
DE60021065D1 (de) Virus behandlung
ATE269391T1 (de) Wäschebehandlung
DE60023454D1 (de) Lagenmaterialen mit tensid-modifizierten chelatbildern behandelt
EP1117431A4 (de) Behandlung von acidose
DE60032884D1 (de) Blutbehandlungssystem
NO20013337L (no) Ny behandling
DE60103685D1 (de) Behandlung von Poriomania
DE60006412D1 (de) Oxazinochinolone zur behandlung von viralen infektionen
NO20013596D0 (no) Slambehandling
DE60023003D1 (de) Haarbehandlungsmittel
DE50005409D1 (de) Hör-behandlungsgerät
DE60011060D1 (de) Virus behandlung
DE60037935D1 (de) Kontinuierliches behandlungssystem
ATE302165T1 (de) Wasserbehandlung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties